Iranian Red Crescent Medical Journal (IRCMJ)

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

FAQ

Peer Review Process

Journal Metrics

News

Author Guidelines

Article Processing Charge

A Narrative Review of Prediction Models for Postoperative Recurrent Venous Thromboembolism

Document Type : Review articles

Authors

Department of Vascular Surgery, West China Hospital, 37 GuoXue Alley, Chengdu 610041, Sichuan Province, China

Abstract

Venous thrombosis has a great impact on patients' quality of life after relapse. The present study summarizes the prediction model of recurrent venous thrombosis published in recent years regarding the applicable population, evaluation index, and predictive performance. It aims to provide a reference for the construction of a more reasonable predictive model and application of venous thrombosis recurrence. A query was conducted on EBSCO, Ovid, PubMed, Wanfang, and CNKI databases using the keywords "Venous Thromboembolism", "Recurrence", and "Prediction Models" to assess the prediction model of recurrent venous thrombosis. A total of five major models related to the recurrence of venous thrombosis were included. The models differed in reliability, validity, scoring method, evaluation method, and scope of application.

Keywords

References
  1. Martins TD, Annichino Bizzacchi JM, Romano AVC, Filho RM. Principal component analysis on recurrent venous thromboembolism. Clin Appl Thromb Hemost. 2019;25:1-9. doi: 10.1177/1076029619895323. [PubMed: 31858829]
  2. Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. a prospective cohort study in 1,626 patients. Hematologica. 2007;92(2):199-205. doi: 10.3324/haematol.10516. [PubMed: 17296569]
  3. Lauber S, Limacher A, Tritschler T, Stalder O, Mean M,
  4. Righini M, et al. Predictors and outcomes of recurrent
  5. venous thromboembolism in elderly patients. Am J Med. 2018;131(6):703-7. doi: 10.1016/j.amjmed.2017.12.015. [PubMed: 29307536]
  6. Cohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. a population-based
  7. cohort study. Thromb Haemost. 2017;117(1):57-65. doi: 10.1160/TH15-08-0686. [PubMed: 27709226]
  8. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease：CHEST guideline and expert panel report. Chest. 2016;149(2):315-52. doi: 10.1016/j.chest.2015.11.026. [PubMed: 26867832]
  9. China Council for the promotion of health foundation, thrombosis and vascular special fund committee of experts, Pulmonary Embolism and Pulmonary Vascular Disease Group Respiratory Society-Chinese Medical Association, Working Committee of Pulmonary Embolism and Pulmonary Vascular Disease of Respiratory Physicians Branch of Chinese Medical Doctors Association. Suggestions on prevention and management of venous thromboembolism in hospital. Natl Medi J Chin. 2018;98(18):1383-8.
  10. Rodger MA, Kahn SR, Wells PS, Anderson DA, Chagnon I, Le Gal G, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ. 2008;179(5):417-26. doi: 10.1503/cmaj.080493. [PubMed: 18725614]
  11. Rodger MA, Scarvelis D, Kahn SR, Wells PS, Anderson DA, Chagnon I, et al. Long-term risk of venous thrombosis after stopping anticoagulants for a first unprovoked event: a multinational cohort. Thromb Rs. 2016;143:152-8. doi: 10.1016/j.thromres.2016.03.028. [PubMed: 27086275]
  12. Rodger MA, Le Gal G, Anderson DR, Schmidt J, Pernod G, Kahn SR, et al. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ. 2017;356:1065. doi: 10.1136/bmj.j1065. [PubMed: 28314711]
  13. Couturaud F, Pernod G, Presles E, Duhamel E, Jego P, Provost K, et al. Six months versus two years of oral anticoagulation after a first episode of unprovoked deep-vein thrombosis. the PADIS-DVT randomized clinical trial. Hematologica. 2019;
  14. (7):1493-501. doi: 10.3324/haematol.2018.210971. [PubMed: 30606789]
  15. Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010;121(14)1630-6. doi: 10.1161/Circulationaha.109.925214. [PubMed: 20351233]
  16. Eichinger S, Heinze G, Kyrle PA. D-dimer levels over time and the risk of recurrent venous thromboembolism: an update of the Vienna prediction model. J Am Heart Assoc. 2014;3(l):1-14. doi: 10.1161/JAHA.113.000467. [PubMed: 24385451]
  17. Tritschler T, Mean M, Limacher A, Rodondi N, Aujesky D. Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna prediction model. Blood. 2015;126(16):1949-51. doi: 10.1182/blood-2015-04-641225. [PubMed: 26341256]
  18. Tosetto A, Iorio A, Marcucci M, Baglin T, Cushman M, Eichinger S, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score(DASH). J Thromb Hemost. 2012;10(6):1019-25. doi: 10.1111/j.1538-7836.2012.04735.x. [PubMed: 22489957]
  19. Tosetto A, Testa S, Martinelli I, Poli D, Cosmi B, Lodigiani C, etal. External validation of the DASH prediction rule: a retrospective cohort study. J Thromb Hemost. 2017;15(10):1963-70. doi: 10.1111/jth.13781. [PubMed: 28762665]
  20. MacDonald S, Chengal R, Hanxhiu A, Symington E, Sheares K, Besser M, et al. Utility of the DASH score after unprovoked venous thromboembolism; a single centre study. Br J Hematol. 2019;185(3):631-3. doi: 10.1111/bjh.15597. [PubMed: 30443905]
  21. Frere C, Benzidia I, Marjanovic Z, Farge D. Recent advances in the management of cancer-associated thrombosis: new hopes but new challenges. Cancers (Basel). 2019,11(1):1-17. doi: 10.3390/cancers11010071. [PubMed: 30634638]
  22. Louzada ML, Carrier M, Lazo Langner A, Dao V, Kovacs MJ, Ramsay TO. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation. 2012;126(4):448-54. doi: 10.1161/Circulationaha.111.051920. [PubMed: 22679142]
  23. Astruc N, Ianotto JC, Metges JP, Lacut K, Delluc A. External validation of the modified ottawa score for risk stratification of recurrent cancer-associated thrombosis. Eur J Intern Med. 2016;36:11-12. doi: 10.1016/j.ejim.2016.08.001. [PubMed: 27592403]
  24. Delluc A, Miranda S, Exter PD, Louzada M, Alatri A, Ahn S, et al. Accuracy of the ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: a systematic review and
  25. meta-analysis. Hematologica. 2020;105(5):1436-42. doi: 10.3324/haematol.2019.222828. [PubMed: 31273089]
  26. Piran S, Schulman S. Management of recurrent venous thromboembolism in patients with cancer: a review. Thromb
  27. Res. 2018;164(1):172-7. doi: 10.1016/j.thromres.2017.12.019. [PubMed: 29703478]
  28. Gran OV, Braekkan SK, Paulsen B, Skille H, Rosendaal
  29. FR, Hansen JB. Occult cancer-related first venous thromboembolism is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost. 2017;15(7):1361-7. doi: 10.1111/jth.13714. [PubMed: 28440069]
  30. Timp JF, Braekkan SK, Lijfering WM, van Hylckama Vlieg A, Hansen JB, Rosendaal FR, et al. Prediction of recurrent venous thrombosis in all patients with a first venous thrombotic
  31. event: the leiden thrombosis recurrence risk prediction model(L-TRRiP). PLoS Med. 2019;16(10):1-22. doi: 10.1371/journal.pmed.1002883. [PubMed: 31603898]
  32. Timp JF, Lijfering WM, Flinterman LE, van Hylckama Vlieg A, le Cessie S, Rosendaal FR, et al. Predictive value of factor VIII levels for recurrent venous thrombosis： results from the MEGA follow-up study. J Thromb Hemost. 2015;13(10):1823-32. doi: 10.1111/jth.13113. [PubMed: 26270389]
  33. Jacobsen BK, Eggen AE, Mathiesen EB, Wilsgaard T, Njolstad I. Cohort profile: the Tromso Study. Int J Epidemiol. 2012;
  34. (4):961-7. doi: 10.1093/ije/dyr049. [PubMed: 21422063]
  35. Ahmad A, Sundquist K, Zoller B, Svensson PJ, Sundquist J, Memon AA. Association between TLR9 rs5743836 polymorphism and risk of recurrent venous thromboe-mbolism. J Thromb Thrombolysis. 2017;44(1):130-8. doi: 10.1007/s11239-017-1491-3. [PubMed: 28321710]
  36. Long B, Koyfman A, Gottlieb M. Risk of recurrent venous thromboembolism and bleeding in cancer patients treated with direct oral anticoagulants versus low-molecular-weight heparin. Acad Emerg Med. 2020;27(2):170-2. doi: 10.1111/acem.13855.
  37. Albertsen IE, Sogaard M, Goldhaber SZ, Piazza G, Skjoth F, Overvad TF, et al. Development of sex-stratified prediction models for recurrent venous throm‌boembolism: a Danish nationwide cohort study. Thromb Haemost. 2020;120(5):805-14. doi: 10.1055/s-0040-1708877. [PubMed: 32369851]
  38. Bradbury C, Fletcher K, Sun Y, Heneghan C, Gardiner C, Roalfe A, et al. A randomized controlled trial of extended anticoagulation treatment versus standard treatment for the prevention of recurrent venous thromboembolism (VTE) and postthrombotic syndrome in patients being treated for a first episode of unprovoked VTE (the ExACT study). BR J Hematol. 2020;188(6):962-75. doi: 10.1111/bjh.16275. [PubMed: 31713863]
  39. Li HY, Li R, Zhi YR, Wang J, Zhang L, Jin Ze, et al. Study on risk prediction model of in-hospital venous thromboembolism in middle-aged and elderly patient. Chin J Nurs. 2020;55(1):68-73. doi: 10.3761/j.issn.0254-1769.2020.01.011.
  40. Tian LY, Wang LQ, Zeng JQ, et al. Research progress in the risk assessment model of venous thromboembolism in children. Chin J Nus. 2020;55(3):462-7.
  41. Shi CL, Zhou HX, Tang YJ, Wang L, Yi Q, Liang ZA. Risk factors for venous thromboembolism recurrence and the predictive value of simplified pulmonary embolism severity index in medical inpatients. Zhonghua Yi Xue Za Zhi. 2016;96(14):1112-5. doi: 10.3760/cma.j.issn.0376-2491.2016.14.010. [PubMed: 27095779]
  42. Cai SN, Zhang YX, Chen X, et al. Research progress of building a prediction model of critically. ill patients' condition change based on big data. Chin J Nurs. 2018;53(11):1382-5.
  43. Wang X, Liu ZY. Introduction and interpretation of guidelines on thromboprophylaxis in the perioperative period of urological surgery. Chin J Surg. 2018;56(1):18-23. doi: 10.3760/cma.j.issn.0529-5815.2018.01.006.
  44. Chinese Medical Association Orthopedic Society. Chinese guidelines for the prevention of venous thromboembolism during major orthopedic operations. Chin J Orthopedics. 2016;(2):65-71.
  45. Cancer and Thrombosis Expert Committee of Chinese Society of Clinical Oncology. Guidelines for the prevention and treatment of tumor-associated venous thromboembolism (2019 edition). Chin J Clini Oncolo. 2019;46(13):653-60.
  46. Zhang M, Wang Y, Huang J, Yin J, Zhu X. Survey of medical staff cognition of the control and treatment of venous thromboembolism at seven general hospitals in Beijing: analysis and countermeasures. Chin J Hospi Administra. 2018;34(6):482-6.
  47. Wang XJ, Xu Y, Chen YP, Deng Bh, Lu XX, Ding MY, et al. A multicenter survey of knowledge about prevention of venous thromboembolism in nurses. Chin J Nurs. 2017;52(12):1500-4.
Iranian Red Crescent Medical Journal (IRCMJ)
Volume 24, Issue 8 - Serial Number 8
2022
Files
History
  • Receive Date: 10 February 2022
  • Revise Date: 26 May 2024
  • Accept Date: 27 January 2024
  • First Publish Date: 27 January 2024
  • Publish Date: 01 August 2022
Share
How to cite
Statistics